Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Maternal Screening Tests included in task force list: 1. First trimester screening by FMF 2. Quadruple marker 3. Trisomy confirmation 4. NIPD (Non-invasive Prenatal Diagnosis) Targeted Specialties Gynecologists (Obstetricians) IVF specialists Stages of Pregnancy • First Trimester – First 3 months (first 12 weeks of pregnancy) • Second Trimester – Next 3 months (13 to 27 weeks) • Third Trimester – Final 3 months (28 weeks to 40 weeks) What is maternal screening? • Certain tests done in pregnant women to identify pregnancies at higher-than-average risk of certain serious birth defects • Also called prenatal screening • Clinical significance – Guides course of action for abnormal pregnancies (including termination of pregnancy in some cases) First Trimester Screening First Trimester Screening Test @ Metropolis Dual or Double Marker Test (with or without NT)– This includes • Free β hCG (Free Beta Human Chorionic Gonadotropin) • PAPP - A (Pregnancy Associated Plasma Protein – A) What is NT? • NT stands for Nuchal Translucency • It is a measurement of the fluid underneath the skin along the back of the baby’s neck • It is measured by ultrasonography Free β hCG (Free Beta Human Chorionic Gonadotropin) • Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone normally produced by placenta during pregnancy • Very early in pregnancy, it is the substance used in pregnancy tests • Consists of two subunits – alpha and beta chain subunits • There is a significant increase in the level for free beta hCG subunit in Trisomy 21 cases; the levels are lower in Trisomy 18 cases PAPP - A (Pregnancy Associated Plasma Protein – A) • As the name suggests, is an important pregnancy protein • The main site of synthesis during pregnancy is placenta. The levels in pregnancy are 150 times higher than those in non-pregnant states • Maternal serum levels of PAPP-A in the first trimester are significantly reduced when a fetus affected by Trisomy 21 or Trisomy 18 is present When is Dual marker done? • The first trimester test is generally done between 11 weeks and 14 weeks of pregnancy What does the test detect? • Dual or Double marker test in first trimester, identifies pregnancies that have a high risk of babies having the following chromosomal abnormalities: • • Trisomy 21 (Down’s syndrome) Combined Trisomy 13 (Patau syndrome)/ Trisomy 18 (Edwards syndrome) Remember, This test is NOT a diagnostic test (it cannot tell whether the baby has any of the above conditions); it only identifies the risk of the baby being affected. A confirmatory test may be needed when the screening test is positive (high risk) Downs syndrome or Trisomy 21 • Babies with Down syndrome have an extra chromosome number 21 (3 chromosome 21 instead of normal 2 chromosome 21) • Causes mental retardation and other medical problems involving the heart, GI system and/or other organs Trisomy 18/13 • More severe than Down syndrome • Cause profound mental retardation and severe birth defects in many organ systems • Few babies with trisomies 13/18 can survive more than a few months Although anyone can have a baby with these chromosomal abnormalities, the chances increase with mother’s age Who should be screened? • Ideally all pregnant women should be screened in first trimester for dual marker and if not done should have a quadruple marker screen • However, if any of the following risk factors are present one should strongly consider having the test: – age 35 or older pregnant females – family history of birth defects – previous child born with a birth defect – History of insulin-dependent (type 1) diabetes prior to pregnancy Reporting and Interpretation of Results Report is generated by PRISCA. This is a software for risk calculation Reporting and Interpretation of Results • MoM (Multiples of Median) is a measure of how far an individual test result deviates from the median (medians are generated from the Indian subpopulation) • 1/250 risk means 1 out of 250 women having similar results and history, one may have abnormality • Trisomy 21: screen positive (below 1/250) • Trisomy 18/13: for screen positive (below 1/100), Detection Rate First trimester- NT measurement, PAPP-A. free beta HCG – 82 to 87% First Trimester Screening by FMF (Fetal Medicine Foundation) • The FMF has set up a process for certification in the measurement of fetal NT to ensure that those performing this ultrasound examination have been adequately trained to do so and that high standards of performance are maintained by continuous education and audit • Once the FMF Certificate of competence in the measurement of NT has been obtained, the doctor/sonographer will be entitled to receive free of charge the FMF software for the calculation of risk of chromosomal abnormalities by a combination of maternal age, fetal NT and first-trimester maternal serum free β-hCG and PAPP-A • The only condition for ongoing certification and use of the software is provision of NT data and images by the sonographer for the purposes of audit • FMF has defined guidelines and protocols for NT measurement and this protocol is widely respected globally • Regular audits of NT images are mandatory • Perkin Elmer is the market leader in India for screening by FMF • It is said to have a detection rate of around 90% for Down syndrome at a false positive rate of 5% Second Trimester Screening Second Trimester Screening Tests @ Metropolis Triple Marker Test (Also called triple screen) - This includes • AFP (Alpha-fetoprotein) • uE3 (unconjugated Estriol) • hCG (Human Chorionic gonadotrophin) Quadruple Marker Test (Also called Quad screen) - This includes • • • • AFP (Alpha-fetoprotein) uE3 (unconjugated Estriol) hCG (Human Chorionic gonadotrophin) Inhibin A AFP (Alpha-fetoprotein) • AFP is a substance made in the liver of the fetus and some amount gets into the mother’s blood • Measuring levels in maternal serum help in screening for Downs syndrome or Edward syndrome or neural tube defects • Normally, low levels of AFP can be found in the blood of a pregnant woman. No AFP (or only a very low level) is generally found in the blood of healthy men or healthy, non pregnant women. • In men, non pregnant women, and children, AFP in the blood can mean certain types of cancer, especially cancer of the testicles, ovaries, stomach, pancreas, or liver are present • AFP levels are increased in Neural tube defects and decreased in Down syndrome and Edward syndrome uE3 (Unconjugated Estriol) • Estriol is a hormone produced by the placenta, using ingredients made by the fetal liver and adrenal glands • Estriol levels are reduced in pregnancies with Down syndrome or Edward syndrome Inhibin - A • Is a protein secreted by the ovary, and is designed to inhibit the production of the hormone FSH by the pituitary • The level of inhibin A is increased in the blood of mothers of fetuses with Down syndrome • A practical advantage of the use of inhibin A as a screening marker is the very small change in average levels of inhibin A with increasing lengths of gestation between 15 and 18 weeks in women with unaffected pregnancies. Inaccuracies in estimating the length of gestation will therefore have a much smaller effect on the calculation of risk estimates than would be the case with a marker such as unconjugated estriol When is Triple/Quadruple marker done? • The first trimester test is generally done between 14 weeks and 22 weeks of pregnancy (Ideal time 15-17 weeks) What does the test detect? • Triple or Quadruple marker tests identify pregnancies that have a high risk of babies having the following abnormalities: • • • Trisomy 21 (Down’s syndrome) Trisomy 18 (Edward syndrome) Neural tube defects Remember, These tests are NOT diagnostic tests (they cannot tell whether the baby has any of the above conditions); it only identifies the risk of the baby being affected. A confirmatory test may be needed when the screening test is positive (high risk) Neural Tube Defect (NTD) • A NTD is an opening in the spinal cord or brain that occurs very early in human development • An NTD develops when the neural tube does not close completely • Two types – Open and Closed • Open- Brain and/or spinal cord are exposed through a defect in the skull or vertebrae • Closed – The spinal defect is covered by skin • Treatment depends on severity of complication. No treatment is available for defects such as anencephaly (absence of a major portion of brain); others may require aggressive surgical management Who should be screened? • Ideally all pregnant women should be screened in first trimester for dual marker and if not done should have a quadruple marker screen • However, if any of the following risk factors are present one should strongly consider having the test: – age 35 or older pregnant females – family history of birth defects – previous child born with a birth defect – History of insulin-dependent (type 1) diabetes prior to pregnancy Reporting and Interpretation of Results Report is generated by PRISCA. This is a software for risk calculation Reporting and Interpretation of Results • 1/250 risk means 1 out of 250 women having similar results and history, one may have abnormality • Trisomy 21: screen positive (below 1/250) • Trisomy 18: for screen positive (below 1/100) • Neural Tube defects – cut-off 2.5 MoM of AFP Summary Quadruple test (2nd trimester) Triple test (2nd trimester) Dual marker test (1st trimester) Screens for Trisomy 21, Trisomy 18, NTD Trisomy 21, Trisomy 18, NTD Trisomy 21 and Trisomy 18/13 Test period 14 to 22 weeks of gestation 14 to 22 weeks of gestation 9 to 13.6 weeks of gestation Ideal time for test 15-17 weeks of gestation 15-17 weeks of gestation 10-11 weeks of gestation Effect of Trisomy 21 on biochemical markers Inhibin A increases, Beta HCG increases, AFP decreases & UE3 normal/ decreases Beta HCG increases, AFP decreases & UE3 normal/ decreases Free Beta HCG increases, PAPPa reduces Sensitivity (Detection rate) 81 % 69% 85% with Age, Free HCG, PAPPa & NT Test Requirements • Peripheral blood • USG report including weeks of gestation, CRL measurements, Nuchal translucency measurements, presence or absence of nasal bone, BPD (biparietal diameter). single/twin pregnancy • Family history or previous history of down syndrome pregnancies. • Weight • LMP (last menstrual period) • Race, Smoking status, Diabetes (type 1 or gestational) status • If invitro fertilisation (IVF) procedure done then age of egg donor What if screening is positive for one of the anomalies? • It does NOT mean that the baby necessarily has one of these conditions • Additional testing such as Chorionic Villus Sampling (CVS) and Amniocentesis may be required • CVS and amniocentesis are diagnostic tests that have greater than 99% accuracy in diagnosing whether the baby has or not a chromosomal abnormality Trisomy confirmation Sample collection • Amniotic fluid: AF should always be aspirated under ultrasound guidance by an experienced and skilled practitioner between 13-17 weeks of gestation. Collect 20-30 ml of AF in sterile centrifuge tube (15 ml capacity, screw cap). Do not add any additives. Call for tubes Sample collection • Usually done at 10-12 weeks of gestation • It is the preferred technique before 15 weeks of gestation • Although it is normally done for testing for Downs syndrome, overall, CVS can detect more than 200 disorders What is Karyotyping? • It is also called chromosomal analysis • Chromosomes are examined microscopically to identify diseases caused by change in number &/or structure of the chromosomes Karyotype image of Trisomy 21